A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 196 participants.

Also called NCT01691755

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 196 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01691755
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Mexico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01691755. Randomized; double masking; primary purpose treatment. Start 2012-11 (registry gives no type); primary completion 2013-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy
Condition
Diabetes Mellitus Type 2
Intervention (Drug)
Placebo
Intervention (Drug)
aleglitazar
Lead sponsor
Hoffmann-La Roche (class: industry)

Record details

Record id
cardio:ct-nct01691755
Content hash
ee537e5c8dd25b0f6dfe7e4efcf74c8a876cfa1e4edff9ccc30033a9c67fc233